EA033102B1 - Pharmaceutic composition with modified delayed and sustained release containing asparaginates - Google Patents
Pharmaceutic composition with modified delayed and sustained release containing asparaginatesInfo
- Publication number
- EA033102B1 EA033102B1 EA201700370A EA201700370A EA033102B1 EA 033102 B1 EA033102 B1 EA 033102B1 EA 201700370 A EA201700370 A EA 201700370A EA 201700370 A EA201700370 A EA 201700370A EA 033102 B1 EA033102 B1 EA 033102B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- shell
- core
- sustained release
- potassium
- pharmaceutical composition
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to pharmaceutics and more specifically to a process of manufacturing a drug product for regulation of metabolic processes associated with potassium and magnesium deficiency. The drug product may be used in therapy, e.g. in cardiology and in sports medicine. The invention proposes a pharmaceutical composition with delayed and sustained release comprising a mixture of potassium and magnesium salts of asparagine acid presented as racemates and/or isomers thereof and/or a mixture thereof. The pharmaceutical composition represents a solid dosage form characterized by targeted release of the active substance and consisting of a core and a shell as a film coating. Pharmacokinetic benefits consist in lower side effects on the gastric mucosa. This is achieved by applying a specially-composed shell that is soluble in the alkaline intestinal medium, and this is also due to the optimally developed ratio of active ingredients and excipients both in the core and in the shell, namely: filler, disintegrant, anti-friction agent - in the core; release modifier, plasticizer, anti-friction agent and coloring agent - in the shell of the solid dosage form.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201700370A EA033102B1 (en) | 2017-08-21 | 2017-08-21 | Pharmaceutic composition with modified delayed and sustained release containing asparaginates |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201700370A EA033102B1 (en) | 2017-08-21 | 2017-08-21 | Pharmaceutic composition with modified delayed and sustained release containing asparaginates |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201700370A1 EA201700370A1 (en) | 2019-02-28 |
EA033102B1 true EA033102B1 (en) | 2019-08-30 |
Family
ID=65443153
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201700370A EA033102B1 (en) | 2017-08-21 | 2017-08-21 | Pharmaceutic composition with modified delayed and sustained release containing asparaginates |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA033102B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2207853C1 (en) * | 2002-04-04 | 2003-07-10 | Акционерное Курганское общество медицинских препаратов и изделий "Синтез" | Pharmaceutical solid composition eliciting anti- arrhythmic activity and method for its preparing |
WO2003074041A1 (en) * | 2002-03-07 | 2003-09-12 | Novartis Ag | Pharmaceutical compositions |
RU2229879C1 (en) * | 2003-02-28 | 2004-06-10 | Закрытое акционерное общество "Биоамид" | Medicinal agent "asparkam-1" for regulation of metabolic processes and method for its preparing |
RU2336076C2 (en) * | 2006-06-22 | 2008-10-20 | Закрытое акционерное общество "Биоамид" | Peroral medical product for offset of magnesium deficiency in organism |
RU2404775C2 (en) * | 2005-05-10 | 2010-11-27 | Новартис Аг | Pharmaceutical compositions, containing imatinib and release moderator |
RU2014105636A (en) * | 2014-02-17 | 2015-08-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Российской академии медицинских наук | PHARMACEUTICAL COMPOSITIONS WITH PROLONGED RELEASE FOR THE TREATMENT OF CEREBROVASCULAR DISORDERS |
-
2017
- 2017-08-21 EA EA201700370A patent/EA033102B1/en not_active IP Right Cessation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003074041A1 (en) * | 2002-03-07 | 2003-09-12 | Novartis Ag | Pharmaceutical compositions |
RU2207853C1 (en) * | 2002-04-04 | 2003-07-10 | Акционерное Курганское общество медицинских препаратов и изделий "Синтез" | Pharmaceutical solid composition eliciting anti- arrhythmic activity and method for its preparing |
RU2229879C1 (en) * | 2003-02-28 | 2004-06-10 | Закрытое акционерное общество "Биоамид" | Medicinal agent "asparkam-1" for regulation of metabolic processes and method for its preparing |
RU2404775C2 (en) * | 2005-05-10 | 2010-11-27 | Новартис Аг | Pharmaceutical compositions, containing imatinib and release moderator |
RU2336076C2 (en) * | 2006-06-22 | 2008-10-20 | Закрытое акционерное общество "Биоамид" | Peroral medical product for offset of magnesium deficiency in organism |
RU2014105636A (en) * | 2014-02-17 | 2015-08-27 | Федеральное государственное бюджетное учреждение "Научно-исследовательский институт фармакологии имени В.В. Закусова" Российской академии медицинских наук | PHARMACEUTICAL COMPOSITIONS WITH PROLONGED RELEASE FOR THE TREATMENT OF CEREBROVASCULAR DISORDERS |
Non-Patent Citations (2)
Title |
---|
RAYMOND C. ROWE et al. Handbook Pharmaceutical Excipients, Pharmaceutical Press and American Pharmacists Association, 2009, no. 6, p. 185, 404, 517, 525-526, 581, 685, 728, 741 * |
Панангин. РЛС он-лайн. 13.07.2015, с. 1-6. Найдено из Интернет: https://www.rlsnat.ru/tn_index_id_2499.htm * |
Also Published As
Publication number | Publication date |
---|---|
EA201700370A1 (en) | 2019-02-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12015502134B1 (en) | Mosapride sustained-release formulation providing pharmacological and clinical effects with once-daily administration | |
TW201038298A (en) | A coating tablet collapsible in the oral cavity | |
JP2014198723A5 (en) | ||
CN106163566A (en) | Stability-enhanced pharmaceutical composition containing Pregabalin and preparation method thereof | |
NZ602833A (en) | Oral formulations of cytidine analogs and methods of use thereof | |
KR20200016378A (en) | Solid Formulation of Carriprazine for Oral Administration | |
JP2015510916A5 (en) | ||
JP2014221827A5 (en) | ||
JP6168673B2 (en) | Arylalkylamine compound-containing pharmaceutical composition | |
CN104434931A (en) | Compound oral solid preparation containing ticagrelor and aspirin and preparation method of solid preparation | |
AR105203A1 (en) | SOLID ORAL FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARATION OF THE SAME | |
JP2019508464A (en) | Combined preparation containing clopidogrel and aspirin | |
KR20130004285A (en) | Rapid-release encapsulation composition | |
JP2008542394A (en) | Controlled release composition of at least one form of venlafaxine | |
JP2016512493A5 (en) | ||
KR20150118160A (en) | Enteric Coated Tablet | |
EA033102B1 (en) | Pharmaceutic composition with modified delayed and sustained release containing asparaginates | |
CN104379138B (en) | Acamprosate formulations, methods of use thereof, and combinations comprising acamprosate formulations | |
JP2019014666A5 (en) | ||
CN105517576A (en) | Ultrafast-disintegrating tablet and method for manufacturing same | |
WO2013098268A3 (en) | Tablets and dry-coated agents | |
NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
TWI740994B (en) | Solid preparation with increasing photostability | |
MX2020003697A (en) | Pharmaceutical formulations comprising opioid receptor agonist as active ingredients, methods of manufacture and therapeutic uses thereof. | |
JP2017511350A5 (en) |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM KG TJ TM |